Binod Pokhrel, MD
Endocrinology, Diabetes & Metabolism · Shreveport, LANPI 1033544465
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 194 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in LA, where the typical reported total is $3,044.
Across 194 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$757
- Corcept Therapeutics$477
- Amgen$428
- Medtronic$389
- Lilly USA, LLC$279
- Abbott$193
- plus $922 from 15 others
What the payments were for
- Food & beverage$3,444100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 49 | $757 |
| Corcept Therapeutics | 24 | $477 |
| Amgen(2 entities) | 23 | $428 |
| Medtronic(2 entities) | 15 | $389 |
| Lilly USA, LLC | 18 | $279 |
| Abbott | 10 | $193 |
| Boehringer Ingelheim | 13 | $190 |
| Xeris Pharmaceuticals, Inc. | 6 | $112 |
| Insulet Corporation | 6 | $112 |
| AstraZeneca | 7 | $101 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $74 |
| Sanofi-aventis U.S. LLC | 4 | $66 |
| AbbVie | 4 | $66 |
| Ascendis Pharma Endocrinology Inc | 3 | $61 |
| Bayer | 2 | $35 |
| Kyowa Kirin, Inc. | 1 | $26 |
| UCB, Inc. | 2 | $25 |
| BETA Bionics, Inc. | 1 | $22 |
| Servier Pharmaceuticals LLC | 1 | $17 |
| Merck | 1 | $13 |
| Mckesson Specialty Care Distribution, LLC | 1 | $3 |
How this compares
$3,444 in reported general payments places this provider in the 50th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 245 | $313,773 |
| JardianceEmpagliflozin | 290 | $234,839 |
| TrulicityDulaglutide | 104 | $142,908 |
| MounjaroTirzepatide | 65 | $84,958 |
| FarxigaDapagliflozin Propanediol | 91 | $83,144 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 44 | $56,741 |
| JanuviaSitagliptin Phosphate | 56 | $42,459 |
| Tresiba Flextouch U-100Insulin Degludec | 67 | $38,550 |
| RybelsusSemaglutide | 18 | $35,942 |
| JanumetSitagliptin Phos/Metformin Hcl | 24 | $35,166 |
| Humalog Kwikpen U-200Insulin Lispro | 22 | $26,255 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 168 | $25,748 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 20 | $23,786 |
| Novolog FlexpenInsulin Aspart | 119 | $22,162 |
| Tresiba Flextouch U-200Insulin Degludec | 27 | $21,761 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $757 | $360,411319 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $190 | $261,513330 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $279 | $232,550195 claims |
| AstraZenecaFarxiga | $101 | $83,14491 claims |
| MerckJanuvia, Janumet | $13 | $77,62580 claims |
| AbbVieSynthroid | $66 | $2,04034 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
Other endocrinology, diabetes & metabolism in Shreveport
- Michelle ChicoShreveport$12K
- Dakota BostonShreveport$4K
- Sirisha Reddy ThambuluruShreveport$3K
- Timothy GilbertBaton Rouge$985K
- Vivian FonsecaNew Orleans$658K
- Abdul KhanHammond$587K
- Marideli ScanlanMarrero$444K
- Justin FontenotLafayette$397K
- Ileana TandronSlidell$205K
- Lane FreyThibodaux$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.